SLANT评分在接受目标温度管理的院外心脏骤停存活者神经预后预测中的外部验证与比较性能:来自亚洲队列的见解
该多中心回顾性队列研究分析了2016至2023年448例接受目标温度管理(TTM)的院外心脏骤停(OHCA)成年患者,评估SLANT评分对出院时不良神经预后的预测性能。主要终点为出院时不良神经预后,发生率为77.9%。SLANT评分预测不良神经预后的AUC为0.797(95%CI 0.746-0.849),五个因子均具有统计学显著性。cutoff≥6.5时特异性53.5%、PPV 86.9%;cutoff提高至8.5时特异性66.7%、PPV 89.6%。作者推荐将评分与其他神经评估结合以改善神经预后判断。
要点
- 在448例接受TTM的OHCA成年患者中,出院时不良神经预后发生率为77.9%。
- SLANT评分预测不良神经预后的AUC为0.797(95%CI 0.746-0.849),与原始SLANT队列性能相当。
- SLANT评分五个因子在预测不良神经预后中均具有统计学显著性。
- cutoff≥6.5时特异性53.5%、PPV 86.9%;cutoff≥8.5时特异性66.7%、PPV 89.6%。
- 作者推荐将SLANT评分与其他神经评估结合以改善神经预后判断。
适用人群与场景
- 接受目标温度管理(TTM)的院外心脏骤停(OHCA)成年存活者。
- 多中心亚洲队列,数据收集自2016年至2023年。
诊断标准与关键阈值
- SLANT评分cutoff≥6.5预测不良神经预后:特异性53.5%,阳性预测值86.9%。
- SLANT评分cutoff≥8.5预测不良神经预后:特异性66.7%,阳性预测值89.6%。
研究设计与关键结果
- 研究类型:多中心回顾性队列研究,分析2016年至2023年数据,纳入448例接受TTM的OHCA成年患者。
- 主要终点出院时不良神经预后发生率为77.9%。
- SLANT评分预测不良神经预后的AUC为0.797(95%CI 0.746-0.849),与原始SLANT队列性能相当。
- SLANT评分五个因子在预测不良神经预后中均具有统计学显著性。
- cutoff≥6.5时特异性53.5%、PPV 86.9%;cutoff提高至8.5时特异性66.7%、PPV 89.6%。
证据类型、等级与局限
- 证据类型:多中心回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者推荐将SLANT评分与其他神经评估结合以改善神经预后判断。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Neurological outcomes after out-of-hospital cardiac arrest (OHCA) depend on multiple factors, including the patient's baseline condition and post-arrest management. The SLANT, developed specifically for OHCA survivors treated with targeted temperature management (TTM), requires further validation, particularly in Asian populations.
METHODS: This multicenter retrospective cohort study analyzed data from 2016 to 2023, examining demographics, pre-arrest conditions, resuscitation events, and laboratory biomarkers following TTM. The primary outcome was defined as a poor neurological outcome at hospital discharge. Model performance was assessed using the area under the receiver operating characteristic curve. Multivariate logistic regression analysis was used to analyze the included variables.
RESULTS: A total of 448 eligible adult patients were included, of whom 77.9% experienced poor neurological outcomes at discharge. The performance of the current cohort was comparable to that of the original SLANT cohort, achieving an area under the curve of 0.797 (95% confidence interval: 0.746-0.849). All five factors of the SLANT score remained statistically significant in predicting poor neurological outcomes. At a cutoff of ≥ 6.5, the SLANT score demonstrated a specificity of 53.5% and positive predictive value (PPV) of 86.9%. Increasing the cutoff value to 8.5 improved the specificity to 66.7% and the PPV to 89.6%.
CONCLUSION: The SLANT showed high PPV for predicting poor neurological outcomes at discharge in patients with OHCA undergoing TTM across a multicenter Asian cohort. Combining the score with other neurological assessments is recommended for improved neuroprognostication.
参考来源
- Ho YJ, Fan CY, Kuo YC, et al. External validation and comparative performance of the SLANT score for neuroprognostication in out-of-hospital cardiac arrest survivors undergoing targeted temperature management: insights from an Asian cohort. J Intensive Care. 2025. PMID: 39953628. doi:10.1186/s40560-025-00778-y
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。